Neuroinflammation gene panel testing revealed the variant in NLRP3 (NM_004895:c.214G>A [p.Val72Met]), previously reported in association with Muckle-Wells syndrome.16 The patient’s medication was changed to IL-1 blockade (anakinra) with normalization of C-reactive protein and serum amyloid A and stable MRI brain imaging appearances. This evidence concerns the gene NLRP3 and Muckle-Wells syndrome.